Followers | 262 |
Posts | 50880 |
Boards Moderated | 20 |
Alias Born | 08/29/2007 |
![](https://investorshub.advfn.com/uicon/108458.png?cb=1482855649)
Wednesday, May 01, 2024 12:55:51 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent AZN News
- FARXIGA approved in the US for the treatment of pediatric type-2 diabetes • Business Wire • 06/12/2024 09:35:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 02:14:48 PM
- TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer • Business Wire • 06/10/2024 11:00:00 AM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:23:12 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 06/04/2024 02:02:42 PM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 • PR Newswire (US) • 06/04/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 02:29:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 02:23:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:35:43 AM
- TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial • Business Wire • 06/02/2024 06:32:00 PM
- IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo • Business Wire • 06/02/2024 12:05:00 PM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy • Business Wire • 06/02/2024 12:00:00 PM
- Cellectis Reports Financial Results for First Quarter 2024 • GlobeNewswire Inc. • 05/28/2024 08:30:00 PM
- ダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示す • Business Wire • 05/28/2024 01:06:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 10:15:06 AM
- Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs • Business Wire • 05/27/2024 08:55:00 PM
- Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux • Business Wire • 05/27/2024 05:14:00 PM
- Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial • Business Wire • 05/27/2024 11:00:00 AM
- AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) • Business Wire • 05/23/2024 05:52:00 PM
- AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) • Business Wire • 05/23/2024 11:00:00 AM
- AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 • Business Wire • 05/22/2024 11:00:00 AM
- アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定 • Business Wire • 05/21/2024 10:44:00 PM
- AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an • Business Wire • 05/21/2024 03:37:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM